{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:42:19Z","timestamp":1792640539030,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research","doi-asserted-by":"publisher","award":["HCP0010"],"award-info":[{"award-number":["HCP0010"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We recently reported that a butanol soluble fraction from the stem of <jats:italic>Cassia occidentalis<\/jats:italic> (CSE-Bu) consisting of osteogenic compounds mitigated methylprednisone (MP)-induced osteopenia in rats, albeit failed to afford complete protection thus leaving a substantial scope for further improvement. To this aim, we prepared an oral formulation that was a lipid-based self-nano emulsifying drug delivery system (CSE-BuF). The globule size of CSE-BuF was in the range of 100\u2013180\u2009nm of diluted emulsion and the zeta potential was \u221228 mV. CSE-BuF enhanced the circulating levels of five osteogenic compounds compared to CSE-Bu. CSE-BuF (50\u2009mg\/kg) promoted bone regeneration at the osteotomy site and completely prevented MP-induced loss of bone mass and strength by concomitant osteogenic and anti-resorptive mechanisms. The MP-induced downregulations of miR29a (the positive regulator of the osteoblast transcription factor, Runx2) and miR17 and miR20a (the negative regulators of the osteoclastogenic cytokine RANKL) in bone was prevented by CSE-BuF. In addition, CSE-BuF protected rats from the MP-induced sarcopenia\u00a0and\/or muscle atrophy by downregulating the skeletal muscle atrogenes, adverse changes in body weight and composition. CSE-BuF did not impact the anti-inflammatory effect of MP. Our preclinical study established CSE-BuF as a prophylactic agent against MP-induced osteopenia and muscle atrophy.<\/jats:p>","DOI":"10.1038\/s41598-019-56853-6","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T11:02:41Z","timestamp":1578913361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A butanolic fraction from the standardized stem extract of Cassia occidentalis L delivered by a self-emulsifying drug delivery system protects rats from glucocorticoid-induced osteopenia and muscle atrophy"],"prefix":"10.1038","volume":"10","author":[{"given":"Subhashis","family":"Pal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Mittapelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-2339","authenticated-orcid":false,"given":"Athar","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapana","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eppalapally","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Maurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-9307","authenticated-orcid":false,"given":"Jiaur R.","family":"Gayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat R.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-0246","authenticated-orcid":false,"given":"Naibedya","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"56853_CR1","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard.2006.069252","volume":"66","author":"T Sokka","year":"2007","unstructured":"Sokka, T. et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann. Rheum. Dis. 66, 1491\u20131496 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"56853_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","volume":"76","author":"A Caplan","year":"2017","unstructured":"Caplan, A., Fett, N., Rosenbach, M., Werth, V. P. & Micheletti, R. G. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. J. Am. Acad. Dermatol. 76, 1\u20139 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"56853_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.rdc.2015.08.005","volume":"42","author":"X Whittier","year":"2016","unstructured":"Whittier, X. & Saag, K. G. Glucocorticoid-induced Osteoporosis. Rheum. Dis. Clin. North. Am. 42, 177\u2013189, x (2016).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"56853_CR4","unstructured":"Arazzi M, et al. [Therapy of glucocorticoid induced osteoporosis]. G. Ital. Nefrol. 34, (2017)."},{"key":"56853_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane, N. E. et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627\u20131633 (1998).","journal-title":"J. Clin. Invest."},{"key":"56853_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jocd.2008.10.002","volume":"12","author":"BR Losada","year":"2009","unstructured":"Losada, B. R. et al. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. J. Clin. Densitom. 12, 63\u201370 (2009).","journal-title":"J. Clin. Densitom."},{"key":"56853_CR7","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","volume":"20","author":"BL Langdahl","year":"2009","unstructured":"Langdahl, B. L. et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos. Int. 20, 2095\u20132104 (2009).","journal-title":"Osteoporos. Int."},{"key":"56853_CR8","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag, K. G. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346\u20133355 (2009).","journal-title":"Arthritis Rheum."},{"key":"56853_CR9","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gluer","year":"2013","unstructured":"Gluer, C. C. et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Min. Res. 28, 1355\u20131368 (2013).","journal-title":"J. Bone Min. Res."},{"key":"56853_CR10","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/art.39726","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag, K. G. et al. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. Arthritis Rheumatol. 68, 2122\u20132128 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"56853_CR11","first-page":"664","volume":"158","author":"AY Sato","year":"2017","unstructured":"Sato, A. Y. et al. Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases. Endocrinology 158, 664\u2013677 (2017).","journal-title":"Endocrinology"},{"key":"56853_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0975-5950.208972","volume":"8","author":"V Singh","year":"2017","unstructured":"Singh, V. Medicinal plants and bone healing. Natl J. Maxillofac. Surg. 8, 4\u201311 (2017).","journal-title":"Natl J. Maxillofac. Surg."},{"key":"56853_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.fitote.2009.09.008","volume":"81","author":"JP Yadav","year":"2010","unstructured":"Yadav, J. P. et al. Cassia occidentalis L.: a review on its ethnobotany, phytochemical and pharmacological profile. Fitoterapia 81, 223\u2013230 (2010).","journal-title":"Fitoterapia"},{"key":"56853_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jep.2019.01.029","volume":"235","author":"S Pal","year":"2019","unstructured":"Pal, S. et al. Extract and fraction of Cassia occidentalis L. (a synonym of Senna occidentalis) have osteogenic effect and prevent glucocorticoid-induced osteopenia. J. Ethnopharmacol. 235, 8\u201318 (2019).","journal-title":"J. Ethnopharmacol."},{"key":"56853_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2013.02.032","volume":"334","author":"F Aqil","year":"2013","unstructured":"Aqil, F., Munagala, R., Jeyabalan, J. & Vadhanam, M. V. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 334, 133\u2013141 (2013).","journal-title":"Cancer Lett."},{"key":"56853_CR16","doi-asserted-by":"publisher","first-page":"e0138189","DOI":"10.1371\/journal.pone.0138189","volume":"10","author":"J Xiong","year":"2015","unstructured":"Xiong, J. et al. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone. PLoS One 10, e0138189 (2015).","journal-title":"PLoS One"},{"key":"56853_CR17","doi-asserted-by":"publisher","first-page":"18934","DOI":"10.1074\/jbc.M115.642090","volume":"290","author":"LI Plotkin","year":"2015","unstructured":"Plotkin, L. I. et al. Inhibition of osteocyte apoptosis prevents the increase in osteocytic receptor activator of nuclear factor kappaB ligand (RANKL) but does not stop bone resorption or the loss of bone induced by unloading. J. Biol. Chem. 290, 18934\u201318942 (2015).","journal-title":"J. Biol. Chem."},{"key":"56853_CR18","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/jbmr.2807","volume":"31","author":"P Cabahug-Zuckerman","year":"2016","unstructured":"Cabahug-Zuckerman, P. et al. Osteocyte Apoptosis Caused by Hindlimb Unloading is Required to Trigger Osteocyte RANKL Production and Subsequent Resorption of Cortical and Trabecular Bone in Mice Femurs. J. Bone Min. Res. 31, 1356\u20131365 (2016).","journal-title":"J. Bone Min. Res."},{"key":"56853_CR19","doi-asserted-by":"publisher","first-page":"24120","DOI":"10.1074\/jbc.M611435200","volume":"282","author":"LI Plotkin","year":"2007","unstructured":"Plotkin, L. I., Manolagas, S. C. & Bellido, T. Glucocorticoids induce osteocyte apoptosis by blocking focal adhesion kinase-mediated survival. Evidence for inside-out signaling leading to anoikis. J. Biol. Chem. 282, 24120\u201324130 (2007).","journal-title":"J. Biol. Chem."},{"key":"56853_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2015.06.022","volume":"81","author":"JY Ko","year":"2015","unstructured":"Ko, J. Y. et al. MicroRNA-29a mitigates glucocorticoid induction of bone loss and fatty marrow by rescuing Runx2 acetylation. Bone 81, 80\u201388 (2015).","journal-title":"Bone"},{"key":"56853_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bone.2014.08.004","volume":"68","author":"C Shi","year":"2014","unstructured":"Shi, C. et al. MicroRNA-17\/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells. Bone 68, 67\u201375 (2014).","journal-title":"Bone"},{"key":"56853_CR22","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1074\/jbc.R117.000366","volume":"293","author":"SA Clayton","year":"2018","unstructured":"Clayton, S. A., Jones, S. W., Kurowska-Stolarska, M. & Clark, A. R. The role of microRNAs in glucocorticoid action. J. Biol. Chem. 293, 1865\u20131874 (2018).","journal-title":"J. Biol. Chem."},{"key":"56853_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.celrep.2014.03.004","volume":"7","author":"O Bereshchenko","year":"2014","unstructured":"Bereshchenko, O. et al. GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-beta signaling. Cell. Rep. 7, 464\u2013475 (2014).","journal-title":"Cell Rep."},{"key":"56853_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2013.01.052","volume":"445","author":"C Mekjaruskul","year":"2013","unstructured":"Mekjaruskul, C. et al. Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2-hydroxypropyl-beta-cyclodextrin. Int. J. Pharm. 445, 1\u201311 (2013).","journal-title":"Int. J. Pharm."},{"key":"56853_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2009.08.035","volume":"383","author":"Y Zhao","year":"2010","unstructured":"Zhao, Y. et al. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of Zedoary essential oil: formulation and bioavailability studies. Int. J. Pharm. 383, 170\u2013177 (2010).","journal-title":"Int. J. Pharm."},{"key":"56853_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/10717540802039089","volume":"15","author":"J Tang","year":"2008","unstructured":"Tang, J. et al. Self-emulsifying drug delivery systems for improving oral absorption of ginkgo biloba extracts. Drug. Deliv. 15, 477\u2013484 (2008).","journal-title":"Drug. Deliv."},{"key":"56853_CR27","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3109\/03639045.2011.643897","volume":"38","author":"H Ma","year":"2012","unstructured":"Ma, H. et al. Design and evaluation of self-emulsifying drug delivery systems of Rhizoma corydalis decumbentis extracts. Drug. Dev. Ind. Pharm. 38, 1200\u20131206 (2012).","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"56853_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10616-014-9694-3","volume":"67","author":"T Goto","year":"2015","unstructured":"Goto, T., Hagiwara, K., Shirai, N., Yoshida, K. & Hagiwara, H. Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology 67, 357\u2013365 (2015).","journal-title":"Cytotechnology"},{"key":"56853_CR29","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jbmr.2183","volume":"29","author":"JY Kim","year":"2014","unstructured":"Kim, J. Y. et al. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation. J. Bone Min. Res. 29, 1541\u20131553 (2014).","journal-title":"J. Bone Min. Res."},{"key":"56853_CR30","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/abbs\/gmx087","volume":"49","author":"X Chen","year":"2017","unstructured":"Chen, X. et al. Emodin promotes the osteogenesis of MC3T3-E1 cells via BMP-9\/Smad pathway and exerts a preventive effect in ovariectomized rats. Acta Biochim. Biophys. Sin. (Shanghai) 49, 867\u2013878 (2017).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"56853_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jnutbio.2009.11.002","volume":"22","author":"TH Kim","year":"2011","unstructured":"Kim, T. H. et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J. Nutr. Biochem. 22, 8\u201315 (2011).","journal-title":"J. Nutr. Biochem."},{"key":"56853_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/mnfr.201400592","volume":"59","author":"LA Nash","year":"2015","unstructured":"Nash, L. A., Sullivan, P. J., Peters, S. J. & Ward, W. E. Rooibos flavonoids, orientin and luteolin, stimulate mineralization in human osteoblasts through the Wnt pathway. Mol. Nutr. Food Res. 59, 443\u2013453 (2015).","journal-title":"Mol. Nutr. Food Res."},{"key":"56853_CR33","doi-asserted-by":"publisher","first-page":"e000014","DOI":"10.1136\/rmdopen-2014-000014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot, K. & Roux, C. Glucocorticoid-induced osteoporosis. RMD Open. 1, e000014 (2015).","journal-title":"RMD Open."},{"key":"56853_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00223-008-9124-7","volume":"82","author":"P Vestergaard","year":"2008","unstructured":"Vestergaard, P., Rejnmark, L. & Mosekilde, L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif. Tissue Int. 82, 249\u2013257 (2008).","journal-title":"Calcif. Tissue Int."},{"key":"56853_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.bone.2009.12.021","volume":"46","author":"R Eastell","year":"2010","unstructured":"Eastell, R. et al. Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46, 929\u2013934 (2010).","journal-title":"Bone"},{"key":"56853_CR36","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1096\/fj.11-182519","volume":"25","author":"J Jia","year":"2011","unstructured":"Jia, J. et al. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 25, 3366\u20133376 (2011).","journal-title":"FASEB J."},{"key":"56853_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bone.2015.02.005","volume":"75","author":"M Piemontese","year":"2015","unstructured":"Piemontese, M. et al. Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone 75, 18\u201326 (2015).","journal-title":"Bone"},{"key":"56853_CR38","first-page":"2907","volume":"85","author":"RS Weinstein","year":"2000","unstructured":"Weinstein, R. S., Nicholas, R. W. & Manolagas, S. C. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab. 85, 2907\u20132912 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"56853_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12020-011-9580-0","volume":"41","author":"RS Weinstein","year":"2012","unstructured":"Weinstein, R. S. Glucocorticoid-induced osteonecrosis. Endocrine 41, 183\u2013190 (2012).","journal-title":"Endocrine"},{"key":"56853_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/jbmr.1547","volume":"27","author":"J Xiong","year":"2012","unstructured":"Xiong, J. & O\u2019Brien, C. A. Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Min. Res. 27, 499\u2013505 (2012).","journal-title":"J. Bone Min. Res."},{"key":"56853_CR41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/MCO.0000000000000230","volume":"19","author":"JY Reginster","year":"2016","unstructured":"Reginster, J. Y., Beaudart, C., Buckinx, F. & Bruyere, O. Osteoporosis and sarcopenia: two diseases or one? Curr. Opin. Clin. Nutr. Metab. Care 19, 31\u201336 (2016).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"56853_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jep.2011.04.070","volume":"136","author":"MG Silva","year":"2011","unstructured":"Silva, M. G. et al. Acute and subacute toxicity of Cassia occidentalis L. stem and leaf in Wistar rats. J. Ethnopharmacol. 136, 341\u2013346 (2011).","journal-title":"J. Ethnopharmacol."},{"key":"56853_CR43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/10717544.2013.861659","volume":"22","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Self-emulsifying drug delivery system and the applications in herbal drugs. Drug. Deliv. 22, 475\u2013486 (2015).","journal-title":"Drug. Deliv."},{"key":"56853_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jchromb.2018.01.035","volume":"1081-1082","author":"HS Cheruvu","year":"2018","unstructured":"Cheruvu, H. S. et al. LC-MS\/MS method for the simultaneous quantification of luteolin, wedelolactone and apigenin in mice plasma using hansen solubility parameters for liquid-liquid extraction: Application to pharmacokinetics of Eclipta alba chloroform fraction. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 1081-1082, 76\u201386 (2018).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"56853_CR45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.biomaterials.2015.03.046","volume":"56","author":"JK Tripathi","year":"2015","unstructured":"Tripathi, J. K. et al. Variants of self-assembling peptide, KLD-12 that show both rapid fracture healing and antimicrobial properties. Biomaterials 56, 92\u2013103 (2015).","journal-title":"Biomaterials"},{"key":"56853_CR46","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.phymed.2013.07.007","volume":"20","author":"MP Khan","year":"2013","unstructured":"Khan, M. P. et al. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone. Phytomedicine 20, 1256\u20131266 (2013).","journal-title":"Phytomedicine"},{"key":"56853_CR47","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00216-003-2224-3","volume":"377","author":"GZ Taicher","year":"2003","unstructured":"Taicher, G. Z., Tinsley, F. C., Reiderman, A. & Heiman, M. L. Quantitative magnetic resonance (QMR) method for bone and whole-body-composition analysis. Anal. Bioanal. Chem. 377, 990\u20131002 (2003).","journal-title":"Anal. Bioanal. Chem."},{"key":"56853_CR48","doi-asserted-by":"publisher","first-page":"10207","DOI":"10.1073\/pnas.1733877100","volume":"100","author":"L Abu-Elheiga","year":"2003","unstructured":"Abu-Elheiga, L., Oh, W., Kordari, P. & Wakil, S. J. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat\/high-carbohydrate diets. Proc. Natl. Acad. Sci. USA 100, 10207\u201310212 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"56853_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ijo.2013.146","volume":"39","author":"MS Baker","year":"2015","unstructured":"Baker, M. S., Li, G., Kohorst, J. J. & Waterland, R. A. Fetal growth restriction promotes physical inactivity and obesity in female mice. Int. J. Obes. (Lond.) 39, 98\u2013104 (2015).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"56853_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bone.2017.08.005","volume":"105","author":"SP China","year":"2017","unstructured":"China, S. P. et al. Globular adiponectin reverses osteo-sarcopenia and altered body composition in ovariectomized rats. Bone 105, 75\u201386 (2017).","journal-title":"Bone"},{"key":"56853_CR51","doi-asserted-by":"crossref","unstructured":"Pal, S. et al. The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts. Biochem Pharmacol (2019).","DOI":"10.1016\/j.bcp.2019.03.024"},{"key":"56853_CR52","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00198-012-2121-8","volume":"24","author":"K Khan","year":"2013","unstructured":"Khan, K. et al. Positive skeletal effects of cladrin, a naturally occurring dimethoxydaidzein, in osteopenic rats that were maintained after treatment discontinuation. Osteoporos. Int. 24, 1455\u20131470 (2013).","journal-title":"Osteoporos. Int."},{"key":"56853_CR53","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S8756-3282(02)00874-8","volume":"31","author":"K Hara","year":"2002","unstructured":"Hara, K., Kobayashi, M. & Akiyama, Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone. 31, 575\u2013581 (2002).","journal-title":"Bone"},{"key":"56853_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bcp.2019.03.024","volume":"164","author":"S Pal","year":"2019","unstructured":"Pal, S. et al. The osteogenic effect of liraglutide involves enhanced mitochondrial biogenesis in osteoblasts. Biochem. Pharmacol. 164, 34\u201344 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"56853_CR55","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1096\/fj.09-134684","volume":"23","author":"E Ayroldi","year":"2009","unstructured":"Ayroldi, E. & Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J. 23, 3649\u20133658 (2009).","journal-title":"FASEB J."},{"key":"56853_CR56","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.mce.2016.09.013","volume":"439","author":"AK Singh","year":"2017","unstructured":"Singh, A. K. et al. Small molecule adiponectin receptor agonist GTDF protects against skeletal muscle atrophy. Mol. Cell. Endocrinol. 439, 273\u2013285 (2017).","journal-title":"Mol. Cell Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56853-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:10:53Z","timestamp":1670303453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56853-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["56853"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56853-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"17 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Although not applicable to this study, Naibedya Chattopadhyay has received (a) consultancy fees from Glenmark Pharmaceuticals, Navi Mumbai, India, (b) consultancy fees from Glaxo Smith Kline-Consumer Healthcare, Gurgaon, India, and (c) served as an Advisory Board Member of Alkem Laboratories Ltd, India. Subhashis Pal, Naresh Mittapelly, Athar Husain, Sapana Kushwaha, Sourav Chattopadhyay, Padam Kumar, Eppalapally Ramakrishna, Sudhir Kumar, Rakesh Maurya, Sabyasachi Sanyal, Jiaur R. Gayen and Prabhat Ranjan Mishra declare that they have no financial and non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}